PET Imaging Tracks Metabolic Decline Across ALS Clinical Stages

Mapping the Metabolic Progression of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis remains a complex clinical syndrome characterized by significant heterogeneity in genetic drivers, molecular pathology, and phenotypic progression [1, 2]. While the King's staging system (a clinical tool that categorizes disease progression based on anatomical spread and functional milestones) provides a framework for tracking clinical milestones, the underlying neurodegenerative spread often precedes overt functional loss [3, 2]. Current diagnostic guidelines highlight the utility of 18F-fluorodeoxyglucose positron emission tomography (a functional imaging technique that measures regional brain glucose metabolism) in differentiating neurodegenerative conditions, yet its role in staging amyotrophic lateral sclerosis is not fully established [4]. Improved biological markers are necessary to bridge the gap between clinical observations and the progressive neuropathological changes occurring in the motor and extra-motor systems [2]. To better characterize this progression, a recent study investigates how metabolic connectivity patterns evolve across clinical stages, offering clinicians a potential new objective tool for tracking disease severity.

Metabolic Gradients and Patient Characteristics

The cross-sectional study analyzed a substantial cohort of 832 patients with amyotrophic lateral sclerosis, a fatal neurodegenerative disease affecting both upper and lower motor neurons. All participants underwent brain 18F-fluorodeoxyglucose positron emission tomography at the time of diagnosis between 2008 and 2022 at the ALS Centre of Turin. To evaluate the relationship between clinical progression and neurodegeneration, the researchers classified the cohort using the King's staging system, which resulted in 337 patients at stage 1, 274 at stage 2, and 221 at stage 3. These groups exhibited significant clinical heterogeneity at the time of imaging, showing distinct differences in age at the time of the scan, disease duration, and functional status as measured by the total ALS Functional Rating Scale Revised (a standard questionnaire measuring physical function in activities of daily living). Beyond clinical milestones, the researchers identified significant biological and cognitive variations across the three stages. The groups differed in their C9ORF72 status (the most common genetic mutation associated with both familial and sporadic forms of the disease) and in the distribution of cognitive categories, reflecting the multi-system nature of the pathology. Using multiple regression analysis to evaluate the relationship between brain metabolism and clinical progression, the study identified a decreasing metabolic gradient from King's stage 1 to King's stage 3. This progressive decline in glucose utilization was localized to a specific cluster encompassing both motor and cognitive areas, providing a metabolic map that correlates with the advancing clinical stages of the disease.

Connectivity Shifts in Temporal and Cerebellar Networks

To further investigate the functional implications of metabolic decline, the researchers utilized inter-regional correlation analysis, a statistical method used to measure how different brain areas communicate or synchronize their activity. By using the clusters of metabolic decline as seed regions, the study mapped how functional networks reorganize as the disease progresses. Because 18F-fluorodeoxyglucose positron emission tomography serves as a marker of neurodegeneration in living patients, these connectivity patterns provide a window into the underlying TDP-43 proteinopathy (the abnormal accumulation of the TDP-43 protein in neurons, which is the primary pathological hallmark of amyotrophic lateral sclerosis). The analysis demonstrated that as the King's stage increases, there is a progressive decrease of connectivity within the sensorimotor and cognitive areas, suggesting a breakdown of established neural networks as clinical disability worsens. The inter-regional correlation analysis specifically highlighted shifting connectivity between motor and cognitive regions and the temporal and cerebellar regions. In King's stage 1, there is clear connectivity with temporal regions; however, this connectivity decreases in King's stage 2 and disappears entirely by King's stage 3. The authors suggest that this steady attrition in temporal involvement likely reflects the anatomical spread of the toxic TDP-43 protein. In contrast, the cerebellar involvement follows a non-linear trajectory. Connectivity with the cerebellum occurs in King's stage 2 and decreases in King's stage 3. This transient recruitment of cerebellar networks in the middle stage of the disease may represent a compensatory mechanism as the brain attempts to maintain motor function despite advancing neurodegeneration.

Clinical Implications for Disease Monitoring

The integration of metabolic imaging into the clinical assessment of amyotrophic lateral sclerosis provides a biological correlate for the King's staging system, which has traditionally relied on observable clinical milestones. By demonstrating that 18F-fluorodeoxyglucose positron emission tomography imaging of the brain can be integrated with clinical staging to assess the extent of the pathogenic process, the study offers a method to bridge the gap between physical symptoms and underlying neurodegeneration. This objective measurement is particularly relevant given that the researchers identified a decreasing metabolic gradient from King's stage 1 to King's stage 3 in a cluster encompassing both motor and cognitive areas. For the practicing clinician, these findings suggest that positron emission tomography imaging can serve as a visible marker of the disease's anatomical spread, reflecting the progressive nature of TDP-43 proteinopathy across the 832 patients studied. Beyond routine diagnosis, these metabolic signatures have significant utility for the design and execution of clinical trials. The researchers suggest that 18F-fluorodeoxyglucose positron emission tomography imaging may be integrated with the King's staging system to assess pathogenic extent in clinical trials, providing a more granular view of patient progression than clinical scales alone. Because the study found that connectivity within sensorimotor and cognitive areas decreases as the King's stage increases, these imaging markers could be used to stratify patients more accurately or to monitor the biological efficacy of neuroprotective therapies. By tracking the disappearance of temporal connectivity or the transient recruitment of the cerebellum, clinicians and researchers can better understand whether a treatment is successfully slowing the metabolic decline that characterizes the transition between clinical stages.

References

1. Tzeplaeff L, Jürs AV, Wohnrade C, Demleitner AF. Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials. Cells. 2024. doi:10.3390/cells13050452

2. Masrori P, Damme PV. Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology. 2020. doi:10.1111/ene.14393

3. Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology Neurosurgery & Psychiatry. 2020. doi:10.1136/jnnp-2019-322541

4. Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.. European journal of neurology. 2018. doi:10.1111/ene.13728